HK Stock MarketDetailed Quotes

01875 TOT BIOPHARM-B

Watchlist
  • 1.510
  • -0.060-3.82%
Not Open Apr 24 16:08 CST
1.17BMarket Cap-27962P/E (TTM)

TOT BIOPHARM-B Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
(Q3)Mar 31, 2022
(FY)Dec 31, 2021
(Q9)Sep 30, 2021
Turnover
76.54%780.63M
77.25%541.98M
80.24%328.06M
65.28%132.63M
479.34%442.18M
744.11%305.78M
686.87%182.02M
450.25%80.25M
239.36%76.33M
--36.23M
Operating income
76.54%780.63M
80.24%328.06M
479.34%442.18M
686.87%182.02M
239.36%76.33M
Cost of sales
-188.76%-206.64M
----
-232.48%-78.06M
----
-46.49%-71.56M
----
-156.79%-23.48M
----
-601.78%-48.85M
----
Operating expenses
-188.76%-206.64M
-232.48%-78.06M
-46.49%-71.56M
-156.79%-23.48M
-601.78%-48.85M
Gross profit
54.87%573.99M
57.69%250M
1,248.97%370.62M
1,033.33%158.54M
76.91%27.47M
Selling expenses
-116.23%-441.02M
----
-181.60%-197.38M
----
-792.62%-203.95M
----
-525.70%-70.09M
----
11.96%-22.85M
----
Administrative expenses
-9.14%-68.31M
----
-21.04%-31.1M
----
-11.10%-62.59M
----
4.19%-25.7M
----
-20.23%-56.34M
----
Research and development expenses
31.28%-103.89M
----
28.89%-49.97M
----
29.59%-151.17M
----
20.82%-70.27M
----
8.71%-214.7M
----
Impairment and provision
-1,823.12%-11.48M
----
152.00%480K
----
---597K
----
---923K
----
----
----
-Other impairment is provision
-1,823.12%-11.48M
----
152.00%480K
----
---597K
----
---923K
----
----
----
Special items of operating profit
104.92%17.65M
----
798.05%13.39M
----
28.39%8.62M
----
156.05%1.49M
----
76.49%6.71M
----
Operating profit
15.40%-33.06M
-109.79%-14.58M
84.95%-39.08M
93.98%-6.95M
10.04%-259.7M
Financing income
31.30%2.97M
----
207.95%1.28M
----
133.75%2.27M
----
-41.88%415K
----
-48.46%969K
----
Financing cost
21.61%-5.18M
----
33.85%-2.26M
----
-167.50%-6.6M
----
-1,147.45%-3.42M
----
-44.67%-2.47M
----
Share of profit from joint venture company
62.39%-2.5M
----
106.88%397K
----
-38,917.65%-6.63M
----
---5.77M
----
---17K
----
Earning before tax
24.56%-37.76M
3.57%-15.16M
80.84%-50.05M
86.33%-15.72M
9.46%-261.22M
Tax
---1K
----
---1K
----
----
----
----
----
----
----
After-tax profit from continuing operations
24.56%-37.76M
3.57%-15.16M
80.84%-50.05M
86.33%-15.72M
9.46%-261.22M
Earning after tax
24.56%-37.76M
22.28%-32.39M
3.57%-15.16M
-247.46%-16.38M
80.84%-50.05M
76.57%-41.68M
86.33%-15.72M
88.97%-4.71M
9.46%-261.22M
-177.9M
Minority profit
----
----
----
----
---130K
----
----
----
----
----
Profit attributable to shareholders
24.36%-37.76M
20.10%-32.39M
3.57%-15.16M
-247.46%-16.38M
80.89%-49.92M
77.21%-40.54M
86.33%-15.72M
-4.71M
9.46%-261.22M
-177.9M
Basic earnings per share
37.50%-0.05
33.33%-0.02
82.61%-0.08
85.00%-0.03
9.80%-0.46
Diluted earnings per share
37.50%-0.05
33.33%-0.02
82.61%-0.08
85.00%-0.03
9.80%-0.46
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
Audit Opinions
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
Auditor
PricewaterhouseCoopers
--
--
--
PricewaterhouseCoopers
--
--
--
PricewaterhouseCoopers
--
(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022(Q3)Mar 31, 2022(FY)Dec 31, 2021(Q9)Sep 30, 2021
Turnover 76.54%780.63M77.25%541.98M80.24%328.06M65.28%132.63M479.34%442.18M744.11%305.78M686.87%182.02M450.25%80.25M239.36%76.33M--36.23M
Operating income 76.54%780.63M80.24%328.06M479.34%442.18M686.87%182.02M239.36%76.33M
Cost of sales -188.76%-206.64M-----232.48%-78.06M-----46.49%-71.56M-----156.79%-23.48M-----601.78%-48.85M----
Operating expenses -188.76%-206.64M-232.48%-78.06M-46.49%-71.56M-156.79%-23.48M-601.78%-48.85M
Gross profit 54.87%573.99M57.69%250M1,248.97%370.62M1,033.33%158.54M76.91%27.47M
Selling expenses -116.23%-441.02M-----181.60%-197.38M-----792.62%-203.95M-----525.70%-70.09M----11.96%-22.85M----
Administrative expenses -9.14%-68.31M-----21.04%-31.1M-----11.10%-62.59M----4.19%-25.7M-----20.23%-56.34M----
Research and development expenses 31.28%-103.89M----28.89%-49.97M----29.59%-151.17M----20.82%-70.27M----8.71%-214.7M----
Impairment and provision -1,823.12%-11.48M----152.00%480K-------597K-------923K------------
-Other impairment is provision -1,823.12%-11.48M----152.00%480K-------597K-------923K------------
Special items of operating profit 104.92%17.65M----798.05%13.39M----28.39%8.62M----156.05%1.49M----76.49%6.71M----
Operating profit 15.40%-33.06M-109.79%-14.58M84.95%-39.08M93.98%-6.95M10.04%-259.7M
Financing income 31.30%2.97M----207.95%1.28M----133.75%2.27M-----41.88%415K-----48.46%969K----
Financing cost 21.61%-5.18M----33.85%-2.26M-----167.50%-6.6M-----1,147.45%-3.42M-----44.67%-2.47M----
Share of profit from joint venture company 62.39%-2.5M----106.88%397K-----38,917.65%-6.63M-------5.77M-------17K----
Earning before tax 24.56%-37.76M3.57%-15.16M80.84%-50.05M86.33%-15.72M9.46%-261.22M
Tax ---1K-------1K----------------------------
After-tax profit from continuing operations 24.56%-37.76M3.57%-15.16M80.84%-50.05M86.33%-15.72M9.46%-261.22M
Earning after tax 24.56%-37.76M22.28%-32.39M3.57%-15.16M-247.46%-16.38M80.84%-50.05M76.57%-41.68M86.33%-15.72M88.97%-4.71M9.46%-261.22M-177.9M
Minority profit -------------------130K--------------------
Profit attributable to shareholders 24.36%-37.76M20.10%-32.39M3.57%-15.16M-247.46%-16.38M80.89%-49.92M77.21%-40.54M86.33%-15.72M-4.71M9.46%-261.22M-177.9M
Basic earnings per share 37.50%-0.0533.33%-0.0282.61%-0.0885.00%-0.039.80%-0.46
Diluted earnings per share 37.50%-0.0533.33%-0.0282.61%-0.0885.00%-0.039.80%-0.46
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards HKASHKASHKASHKASHKASHKASHKASHKASHKASHKAS
Audit Opinions Unqualified Opinion------Unqualified Opinion------Unqualified Opinion--
Auditor PricewaterhouseCoopers------PricewaterhouseCoopers------PricewaterhouseCoopers--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg